Loading…
Lobbying Spend
—
Filings
39
Firms Hired
1
Active Period
2015–2024
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Safe Step Act
2023 · third_quarter · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Policies and regulations impacting drugs for rare diseases and conditions; pharmaceutical pricing issues; 340B; Safe Step Act - HR 2630/S 652; FTC regulation of biopharma mergers and acquisitions
Client expense: — · Firm income: $40,000
Matched citations: HR 2630
Policies and regulations impacting drugs for rare diseases and conditions; pharmaceutical pricing issues; 340B; Safe Step Act - HR 2630/S 652; FTC regulation of biopharma mergers and acquisitions
Client expense: — · Firm income: $40,000
Matched citations: S 652
Safe Step Act
2023 · second_quarter · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Policies and regulations impacting drugs for rare diseases and conditions; pharmaceutical pricing issues; 340B; Safe Step Act - HR 2630/S 652
Client expense: — · Firm income: $40,000
Matched citations: HR 2630
Safe Step Act
2023 · second_quarter · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Policies and regulations impacting drugs for rare diseases and conditions; pharmaceutical pricing issues; 340B; Safe Step Act - HR 2630/S 652
Client expense: — · Firm income: $40,000
Matched citations: S 652
Safe Step Act
2022 · fourth_quarter · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Policies and regulations impacting drugs for rare diseases and conditions; pharmaceutical pricing and supply chain issues; Safe Step Act - HR 2163/S 464
Client expense: — · Firm income: $40,000
Matched citations: HR 2163
Safe Step Act
2022 · fourth_quarter · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Policies and regulations impacting drugs for rare diseases and conditions; pharmaceutical pricing and supply chain issues; Safe Step Act - HR 2163/S 464
Client expense: — · Firm income: $40,000
Matched citations: S 464
Safe Step Act
2022 · third_quarter · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Policies and regulations impacting drugs for rare diseases and conditions; pharmaceutical pricing and supply chain issues; 340B Drug Pricing Program, Safe Step Act - HR 2163/S 464
Client expense: — · Firm income: $40,000
Matched citations: HR 2163
Policies and regulations impacting drugs for rare diseases and conditions; pharmaceutical pricing and supply chain issues; 340B Drug Pricing Program, Safe Step Act - HR 2163/S 464
Client expense: — · Firm income: $40,000
Matched citations: S 464
Pharmaceutical pricing issues; HR 748, the CARES Act; access to infused medications in the home setting
Client expense: — · Firm income: $40,000
Matched citations: HR 748
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
2017 · fourth_quarter · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
HR 1, Tax Cuts and Jobs Act
Client expense: — · Firm income: $60,000
Matched citations: HR 1
RACE for Children Act
2017 · third_quarter · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
S 934/HR 2430, FDA Reauthorization Act of 2017; S 456/HR 1231, RACE for Children Act; 340B drug pricing program; Better Care Reconciliation Act
Client expense: — · Firm income: $60,000
Matched citations: HR 1231
FDA Reauthorization Act of 2017
2017 · third_quarter · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
S 934/HR 2430, FDA Reauthorization Act of 2017; S 456/HR 1231, RACE for Children Act; 340B drug pricing program; Better Care Reconciliation Act
Client expense: — · Firm income: $60,000
Matched citations: HR 2430
RACE for Children Act
2017 · third_quarter · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
S 934/HR 2430, FDA Reauthorization Act of 2017; S 456/HR 1231, RACE for Children Act; 340B drug pricing program; Better Care Reconciliation Act
Client expense: — · Firm income: $60,000
Matched citations: S 456
FDA Reauthorization Act of 2017
2017 · third_quarter · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
S 934/HR 2430, FDA Reauthorization Act of 2017; S 456/HR 1231, RACE for Children Act; 340B drug pricing program; Better Care Reconciliation Act
Client expense: — · Firm income: $60,000
Matched citations: S 934
FDA Reauthorization Act of 2017
2017 · second_quarter · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to S. 934, PDFUA/Race Act, drug importation, 340B, The Better Care Reconciliation Act, orphan drug policies, and pharmaceutical pricing.
Client expense: — · Firm income: $60,000
Matched citations: S. 934
Source: Senate LDA